S&P Rises as Economic Data, Positive Vaccine Results Overshadow Rising Cases

Marco Green
July 3, 2020

The COVID-19 vaccine developed by German biotech firm BioNTech and the USA pharmaceutical giant has shown potential and was found to be well tolerated in early-stage human trials testing of 45 people.

There were 45 healthy adults included in the study, with 24 administered two doses of 10 and 30 µg, 12 who received a single 100 µg, and nine who were the placebo control.

The companies announced these preliminary findings on Wednesday in a pre-print paper that shows participants in a Phase 1/2 study of the vaccine, called BNT162b1, responded to the immunization and it was found to be well tolerated.

Pfizer and Germany's BioNTech are in a race with companies including AstraZeneca Plc, Moderna Inc. and dozens of other biopharmaceutical outfits and academic groups to come up with a safe and effective vaccine against covid-19.

European stock markets are set to edge higher at the open Thursday, helped by positive results from a potential Covid-19 vaccine although sentiment remains cautious as coronavirus cases mount ahead of the release of key USA employment data.

Those who received the 10 and 30 microgram doses were given two injections, while those who got the larger dose only got one.

Among several RNA-based SARS-CoV-2 vaccine candidates that are now being studied and that are considered favorable to enter a safety and efficacy trial, BNT162b1 was quickly shown to be one of the most promising ones.

BNT162b1 is a lipid nanoparticle-formulated, nucleoside-modified mRNA (modRNA) vaccine candidate that encodes trimerized SARS-CoV-2 spike glycoprotein receptor binding domain (RBD) antigen.

The GMC data from this cohort was reported to be eight and 46.3 times higher than the GMC in a panel of participants who had contracted the virus. According to the report, the five will receive additional government funding, assistance with clinical trials, and financial and logistical support for manufacturing. "We look forward to providing further data updates on BNT162b1".

Bourla also said: "If things go well, and the stars are aligned, we will have enough evidence of safety and efficacy so that we can... have a vaccine around the end of October". BioNTech and Pfizer continue to ramp up manufacturing capacity, with plans to produce up to 100 million doses by the end of 2020 and over 1.2 billion by the end of 2021.

Other reports by Click Lancashire

Discuss This Article